Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer

References

• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Wu FTH, Stefanini MO, Mac Gabhann F et al. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J. Cell. Mol. Med.14(3), 528–552 (2010).
   PubMedGoogle Scholar
• Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J. Clin. Oncol.24(9), 1329–1331 (2006).
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Willett CG et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol.6(6), 327–338 (2009).
   PubMed Web of Science ®Google Scholar
• Widakowich C, de Castro G Jr, de Azambuja E, Dinh P, Awada A. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist12(12), 1443–1455 (2007).
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis.49(2), 186–193 (2007).
   PubMed Web of Science ®Google Scholar
• Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354(9), 980–982; discussion 980–982 (2006).
   PubMed Web of Science ®Google Scholar
• Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N. Engl. J. Med.354(9), 980–982; discussion 980–982 (2006).
   PubMedGoogle Scholar
• Bose D, Meric-Bernstam F, Hofstetter W et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol.11(4), 373–382 (2010).
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol.10(2), 157–163 (2009).
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med.358(11), 1129–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol.9(2), 117–123 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI. Quantifying hypertension in patients with cancer treated with sorafenib. Lancet Oncol.9(2), 86–87 (2008).
   PubMedGoogle Scholar
• Beevers G, Lip GY, O’Brien E. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors common to all techniques. BMJ322(7292), 981–985 (2001).
   PubMed Web of Science ®Google Scholar
• Chang JJ, Rabinowitz D, Shea S. Sources of variability in blood pressure measurement using the Dinamap PRO 100 automated oscillometric device. Am. J. Epidemiol.158(12), 1218–1226 (2003).
   PubMedGoogle Scholar
• Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43–9006. J. Clin. Oncol.24(9), 1363–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Azizi M, Chedid A, Oudard S. Home blood-pressure monitoring in patients receiving sunitinib. N. Engl. J. Med.358(1), 95–97 (2008).
   PubMed Web of Science ®Google Scholar
• Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr. Hypertens. Rep.9(4), 320–328 (2007).
   PubMedGoogle Scholar
• Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol.28(22), 3617–3622 (2010).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol.27(13), 2231–2237 (2009).
   PubMed Web of Science ®Google Scholar
• Chaplain MA, McDougall SR, Anderson AR. Mathematical modeling of tumor-induced angiogenesis. Annu. Rev. Biomed. Eng.8, 233–257 (2006).
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis9(4), 225–230; discussion 231 (2006).
   PubMedGoogle Scholar
• Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene5(4), 519–524 (1990).
   PubMed Web of Science ®Google Scholar
• Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA90(22), 10705–10709 (1993).
   PubMed Web of Science ®Google Scholar
• Helske S, Vuorela P, Carpen O et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol. Hum. Reprod.7(2), 205–210 (2001).
   PubMed Web of Science ®Google Scholar
• Thomas CP, Andrews JI, Liu KZ. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J.21(14), 3885–3895 (2007).
   PubMedGoogle Scholar
• Sela S, Itin A, Natanson-Yaron S et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res.102(12), 1566–1574 (2008).
   PubMed Web of Science ®Google Scholar
• Heydarian M, McCaffrey T, Florea L et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta30(3), 250–255 (2009).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med.350(7), 672–683 (2004).
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med.355(10), 992–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.111(5), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem.278(15), 12605–12608 (2003).
   PubMed Web of Science ®Google Scholar
• Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised Phase II study. Lancet371(9630), 2101–2108 (2008).
   PubMed Web of Science ®Google Scholar
• Rini BI SJ, Fruehauf JP, Cohen EE et al. Association of diastolic blood pressure (dBP) > 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736). J. Clin. Oncol.26(15S ), 3543 (2008).
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol.26(28), 4672–4678 (2008).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Bando H, Mori T et al. Overexpression of soluble vascular endothelial growth factor receptor 1 in colorectal cancer: association with progression and prognosis. Cancer Sci.98(3), 405–410 (2007).
   PubMedGoogle Scholar
• Toi M, Bando H, Ogawa T et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer98(1), 14–18 (2002).
   PubMed Web of Science ®Google Scholar
• Lamszus K, Ulbricht U, Matschke J et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin. Cancer Res.9(4), 1399–1405 (2003).
   PubMed Web of Science ®Google Scholar
• Hu Q, Dey AL, Yang Y et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer100(9), 1884–1891 (2004).
   PubMed Web of Science ®Google Scholar
• Bando H, Weich HA, Brokelmann M et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Brit. J. Cancer92(3), 553–561 (2005).
   PubMed Web of Science ®Google Scholar
• Nagaoka S, Yoshida T, Akiyoshi J et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol. Rep.23(6), 1647–1654 (2010).
   PubMed Web of Science ®Google Scholar
• Chang YT, Chang MC, Wei SC et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas37(2), 145–150 (2008).
   PubMed Web of Science ®Google Scholar
• Aref S, El Sherbiny M, Goda T et al. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology10(2), 131–134 (2005).
   PubMed Web of Science ®Google Scholar
• Kim WJ, Yockman JW, Jeong JH et al. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g–PEG–RGD/pCMV–sFlt-1 complexes in tumor-bearing mice. J. Control. Release114(3), 381–388 (2006).
   PubMed Web of Science ®Google Scholar
• Kommareddy S, Amiji M. Antiangiogenic gene therapy with systemically administered sFlt-1 plasmid DNA in engineered gelatin-based nanovectors. Cancer Gene Ther.14(5), 488–498 (2007).
   PubMed Web of Science ®Google Scholar
• Takayama K, Ueno H, Nakanishi Y et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res.60(8), 2169–2177 (2000).
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Farnebo F, Yu EY et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl Acad. Sci. USA98(8), 4605–4610 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zou W, Wang J et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol. Ther.11(4), 553–562 (2005).
   PubMedGoogle Scholar
• Sako A, Kitayama J, Koyama H et al. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res.64(10), 3624–3628 (2004).
   PubMedGoogle Scholar
• Hoshida T, Sunamura M, Duda DG et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble Flt-1 vascular endothelial growth factor receptor. Pancreas25(2), 111–121 (2002).
   PubMed Web of Science ®Google Scholar
• Oba M, Vachutinsky Y, Miyata K et al. Antiangiogenic gene therapy of solid tumor by systemic injection of polyplex micelles loading plasmid DNA encoding soluble Flt-1. Mol. Pharm.7(2), 501–509 (2010).
   PubMedGoogle Scholar
• Mahendra G, Kumar S, Isayeva T et al. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor. Cancer Gene Ther.12(1), 26–34 (2005).
   PubMed Web of Science ®Google Scholar
• Takei Y, Mizukami H, Saga Y et al. Suppression of ovarian cancer by muscle-mediated expression of soluble VEGFR-1/Flt-1 using adeno-associated virus serotype 1-derived vector. Int. J. Cancer120(2), 278–284 (2007).
   PubMedGoogle Scholar
• Sallinen H, Anttila M, Narvainen J et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther.17(2), 278–284 (2009).
   PubMed Web of Science ®Google Scholar
• Mahasreshti PJ, Navarro JG, Kataram M et al. Adenovirus-mediated soluble Flt-1 gene therapy for ovarian carcinoma. Clin. Cancer Res.7(7), 2057–2066 (2001).
   PubMed Web of Science ®Google Scholar
• Mahasreshti PJ, Kataram M, Wang MH et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin. Cancer Res.9(7), 2701–2710 (2003).
   PubMed Web of Science ®Google Scholar
• Liu JR, Li J, Su C, Huang BH, Luo SK. Soluble fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice. Acta Bioch. Bioph. Sin.39(7), 499–506 (2007).
   PubMedGoogle Scholar
• Gao ZN, Wei YQ, Yang PS et al. Combined effects of soluble vascular endothelial growth factor receptor Flt-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Oral Oncol.43(5), 477–483 (2007).
   PubMedGoogle Scholar
• Bertin S, Mohsen-Kanson T, Baque P et al. Tumor microenvironment modifications induced by soluble VEGF receptor expression in a rat liver metastasis model. Cancer Lett.298(2), 264–272 (2010).
   PubMedGoogle Scholar
• Hasumi Y, Mizukami H, Urabe M et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res.62(7), 2019–2023 (2002).
   PubMed Web of Science ®Google Scholar
• Yin D, Jia T, Gong W et al. VEGF blockade decelerates the growth of a murine experimental osteosarcoma. Int. J. Oncol.33(2), 253–259 (2008).
   PubMedGoogle Scholar
• Ye C, Feng C, Wang S et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology145(2), 817–822 (2004).
   PubMed Web of Science ®Google Scholar
• Hu M, Yang JL, Teng H et al. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer8, 306 (2008).
   PubMedGoogle Scholar
• Zhu AX, Sahani DV, Duda DG et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a Phase II study. J. Clin. Oncol.27(18), 3027–3035 (2009).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol.28(17), 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Duda DG, Willett CG, Ancukiewicz M et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist15(6), 577–583 (2010).
   PubMedGoogle Scholar
• Willett CG, Duda DG, di Tomaso E et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary Phase II study. J. Clin. Oncol.27(18), 3020–3026 (2009).
   PubMed Web of Science ®Google Scholar
• Hornig C, Behn T, Bartsch W, Yayon A, Weich HA. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J. Immunol. Methods226(1–2), 169–177 (1999).
   PubMedGoogle Scholar